Estimating alcohol-attributable liver disease mortality: A comparison of methods.


Journal

Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440

Informations de publication

Date de publication:
07 2022
Historique:
revised: 15 03 2022
received: 17 10 2021
accepted: 16 03 2022
pubmed: 2 4 2022
medline: 8 7 2022
entrez: 1 4 2022
Statut: ppublish

Résumé

Alcohol is a leading contributor to liver disease, however, estimating the proportion of liver disease deaths attributable to alcohol use can be methodologically challenging. We compared three approaches for estimating alcohol-attributable liver disease deaths (AALDD), using the USA as an example. One involved summing deaths from alcoholic liver disease and a proportion from unspecified cirrhosis (direct method); two used population attributable fraction (PAF) methodology, including one that adjusted for per capita alcohol sales. For PAFs, the 2011-2015 Behavioral Risk Factor Surveillance System and per capita sales from the Alcohol Epidemiologic Data System were used to derive alcohol consumption prevalence estimates at various levels (excessive alcohol use was defined by medium and high consumption levels). Prevalence estimates were used with relative risks from two meta-analyses, and PAFs were applied to the 2011-2015 average annual number of deaths from alcoholic cirrhosis and unspecified cirrhosis (using National Vital Statistics System data) to estimate AALDD. The number of AALDD was higher using the direct method (28 345 annually) than the PAF methods, but similar when alcohol prevalence was adjusted using per capita sales and all alcohol consumption levels were considered (e.g. 25 145 AALDD). Using the PAF method, disaggregating non-drinkers into lifetime abstainers and former drinkers to incorporate relative risks for former drinkers yielded higher AALDD estimates (e.g. 27 686) than methods with all non-drinkers combined. Using PAF methods that adjust for per capita sales and model risks for former drinkers yield more complete and possibly more valid AALDD estimates.

Identifiants

pubmed: 35363378
doi: 10.1111/dar.13470
pmc: PMC9253033
mid: NIHMS1807842
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1245-1253

Subventions

Organisme : CDC HHS
ID : 75D30120P09906
Pays : United States
Organisme : Intramural CDC HHS
ID : 75D30120P09906
Pays : United States
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

© 2022 Australasian Professional Society on Alcohol and other Drugs.

Références

Addiction. 2018 Dec;113(12):2245-2249
pubmed: 30014539
J Stud Alcohol. 2000 Jan;61(1):111-20
pubmed: 10627104
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1831-1841.e5
pubmed: 31734449
J Stud Alcohol. 1984 May;45(3):199-208
pubmed: 6748660
J Stud Alcohol Drugs. 2020 May;81(3):339-351
pubmed: 32527386
Lancet Public Health. 2020 Jun;5(6):e316-e323
pubmed: 32504584
J Stud Alcohol. 2003 May;64(3):367-74
pubmed: 12817825
Addiction. 2017 Feb;112(2):207-214
pubmed: 27316346
Drug Alcohol Rev. 2010 Jul;29(4):437-45
pubmed: 20636661
J Stud Alcohol Drugs. 2019 Sep;80(5):552-556
pubmed: 31603757
Drug Alcohol Rev. 2021 Nov;40(7):1377-1386
pubmed: 33783063
J Subst Abuse. 1995;7(3):281-92
pubmed: 8749788
Addiction. 2006 Dec;101(12):1711-8
pubmed: 17156170
J Clin Gastroenterol. 2010 Apr;44(4):301-7
pubmed: 19745759
Alcohol Alcohol Suppl. 1991;1:331-4
pubmed: 1845557
Prev Chronic Dis. 2015 Oct 15;12:E177
pubmed: 26469950
Addiction. 2014 Oct;109(10):1657-66
pubmed: 24825591
J Hepatol. 2019 Feb;70(2):223-236
pubmed: 30658724
Am J Gastroenterol. 2019 Oct;114(10):1574-1586
pubmed: 31464740
J Stud Alcohol Drugs. 2022 Jan;83(1):134-144
pubmed: 35040769
Biomedicines. 2019 Dec 13;7(4):
pubmed: 31847084
N Engl J Med. 2018 Sep 27;379(13):1251-1261
pubmed: 30257164
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
J Hepatol. 2017 Sep;67(3):454-461
pubmed: 28396173
Addiction. 2010 Sep;105(9):1589-96
pubmed: 20626370
Hepatology. 2008 Apr;47(4):1150-7
pubmed: 18264998
Clin Liver Dis (Hoboken). 2021 Jun 04;17(5):365-370
pubmed: 34136143
Gastroenterology. 2021 Jul;161(1):350-352
pubmed: 33753104
Br J Addict. 1989 Sep;84(9):969-77
pubmed: 2624626

Auteurs

Adam Sherk (A)

Canadian Institute for Substance Use Research, Victoria, Canada.

Marissa B Esser (MB)

National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, USA.

Tim Stockwell (T)

Canadian Institute for Substance Use Research, Victoria, Canada.

Timothy S Naimi (TS)

Canadian Institute for Substance Use Research, Victoria, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH